GenomOncology is in the personalized medicine space with a proprietary technology platform to rapidly analyze sequenced genomic data for use in cancer treatment. The platform enables users to browse, filter, and map variations at many different levels to discover the genetic mutations that are unique to the tumor. From this analysis, the company generates a customizable report, including findings and clinical recommendations based on the observed actionable mutations in the tumor genome. Considering cancer is a disease of genetic mutation, this type of personalized approach represents the future of oncology.
GenomOncology has received investment from the North Coast Angel Fund and the Jumpstart Evergreen, Next, and Focus funds.